These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 1848372

  • 21. Neurologic protection by amifostine.
    DiPaola RS, Schuchter L.
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):82-8. PubMed ID: 10348265
    [Abstract] [Full Text] [Related]

  • 22. High-dose cisplatin and vinblastine plus amifostine for metastatic non-small cell lung cancer.
    Schiller JH.
    Semin Oncol; 1996 Aug; 23(4 Suppl 8):78-82. PubMed ID: 8783672
    [Abstract] [Full Text] [Related]

  • 23. High-dose cisplatin with diethyldithiocarbamate (DDTC) rescue therapy: preliminary pharmacologic observations.
    DeGregorio MW, Gandara DR, Holleran WM, Perez EA, King CC, Wold HG, Montine TJ, Borch RF.
    Cancer Chemother Pharmacol; 1989 Aug; 23(5):276-8. PubMed ID: 2539912
    [Abstract] [Full Text] [Related]

  • 24. Study of cisplatin-vinblastine plus amifostine in patients with locally advanced or metastatic non-small cell lung cancer.
    Thongprasert S, Chewaskulyong B.
    J Med Assoc Thai; 2004 Oct; 87(10):1162-7. PubMed ID: 15560691
    [Abstract] [Full Text] [Related]

  • 25. Chemoprotection in anticancer therapy: the emerging role of amifostine (WR-2721).
    Kurbacher CM, Mallmann PK.
    Anticancer Res; 1998 Oct; 18(3C):2203-10. PubMed ID: 9703784
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. [Can cisplatin renal toxicity be prevented?].
    Brillet G, Deray G, Bunker D, Ben Hmida M, Baumelou A, Jacobs C.
    Nephrologie; 1991 Oct; 12(3):143-6. PubMed ID: 1922654
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. [Preclinical and clinical evaluation of toxicity and antitumor activity of cisplatin analogues].
    Ariyoshi Y, Ota K.
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1379-85. PubMed ID: 2658826
    [Abstract] [Full Text] [Related]

  • 34. Org.2766 protects from cisplatin-induced neurotoxicity in rats.
    de Koning P, Neijt JP, Jennekens FG, Gispen WH.
    Exp Neurol; 1987 Sep; 97(3):746-50. PubMed ID: 3040462
    [Abstract] [Full Text] [Related]

  • 35. Chemoprotectants: a review of their clinical pharmacology and therapeutic efficacy.
    Links M, Lewis C.
    Drugs; 1999 Mar; 57(3):293-308. PubMed ID: 10193684
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Phase I/II trials of WR-2721 and cis-platinum.
    Glover D, Glick JH, Weiler C, Fox K, Turrisi A, Kligerman MM.
    Int J Radiat Oncol Biol Phys; 1986 Aug; 12(8):1509-12. PubMed ID: 3019969
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Protective effects of a neurotrophic ACTH(4-9) analog on cisplatin ototoxicity in relation to the cisplatin dose: an electrocochleographic study in albino guinea pigs.
    Stengs CH, Klis SF, Huizing EH, Smoorenburg GF.
    Hear Res; 1998 Oct; 124(1-2):108-17. PubMed ID: 9822908
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.